Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

18 trials with published results (8%)

Research Maturity

99 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.6%

13 terminated out of 233 trials

Success Rate

88.4%

+1.9% vs benchmark

Late-Stage Pipeline

8%

18 trials in Phase 3/4

Results Transparency

18%

18 of 99 completed with results

Key Signals

18 with results88% success13 terminated

Data Visualizations

Phase Distribution

184Total
Not Applicable (59)
P 1 (29)
P 2 (78)
P 3 (16)
P 4 (2)

Trial Status

Completed99
Unknown74
Recruiting25
Terminated13
Active Not Recruiting9
Not Yet Recruiting6

Trial Success Rate

88.4%

Benchmark: 86.5%

Based on 99 completed trials

Clinical Trials (233)

Showing 20 of 20 trials
NCT06157892Phase 2Recruiting

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT03030404CompletedPrimary

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

NCT07007182Phase 2Recruiting

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

NCT06576921Phase 2RecruitingPrimary

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

NCT06131840Phase 1Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT04389632Phase 1Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT07213791Phase 1Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT01950572Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT07504913RecruitingPrimary

Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41

NCT04949737RecruitingPrimary

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

NCT07482566Not ApplicableRecruiting

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

NCT03675737Phase 3CompletedPrimary

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT06885697Phase 1Recruiting

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT07161479Not ApplicableRecruiting

Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)

NCT07309185Phase 2RecruitingPrimary

Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy

NCT06630130Phase 2RecruitingPrimary

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

NCT07260461Not ApplicableNot Yet RecruitingPrimary

The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.

NCT04809025RecruitingPrimary

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

NCT04710758Not ApplicableRecruitingPrimary

Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer

NCT07183358Not ApplicableNot Yet RecruitingPrimary

Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer

Scroll to load more

Research Network

Activity Timeline